Seagen gets FDA accelerated approval for tucatinib, trastuzumab combo for colorectal cancer
American biotechnology company Seagen (formerly Seattle Genetics) has received accelerated approval from the US Food and Drug Administration (FDA) for the company’s oral drug Tukysa (tucatinib) in combination with trastuzumab. Tukysa in combination with trastuzumab is indicated for the treatment of adult patients with RASwild-type, HER2-positive unresectable or metastatic colorectal cancer, which has advanced following […]